• Aethlon Medical reported similar biomarker shifts in cohort 2 of its Australian oncology feasibility study of Hemopurifier in advanced solid tumors.
• Observed reductions in tumor-related extracellular vesicles, including PD-L1-positive vesicles, with increases in T-cell measures that generally persisted through eight weeks.
• Enrollment continues in the third and final cohort; an independent statistical analysis is planned once all cohorts are completed to assess a dose-response signal.
• Results remain preliminary; the study is not designed to show clinical efficacy or patient-outcome benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA02512) on July 13, 2026, and is solely responsible for the information contained therein.